{reportSlug=global-biosimilars-treatment-market, reportId=103615, mktKeyword=Biosimilars Treatment, cagr=0.00, publishDate=Mar 2024, priceOption2=7500, reportTitle=Biosimilars Treatment Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons}, Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin}, Recombinant Peptides {Glucagon, Calcitonin}), Application (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other), Manufacturing (In-House Manufacturing, Contract Manufacturing) Players and Region - Global Market Outlook to 2030, baseYr=2023, totalTableFig=210, priceOption1=3750, forecastYr=2030, noOfPages=210, reportKey=103136, breadcrum=Global Biosimilars Treatment Market}
We do not share your information with anyone. However, we may send you
emails based on your report interest from time to time. You may contact
us at any time to opt-out.
Select User Access Type
Key Highlights of Report
Mar 2024
210 Pages
81 Tables
Base Year: 2023Coverage: 15+ Companies; 18
Countries